These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1114 related articles for article (PubMed ID: 27110920)

  • 1. The prevalence of irritable bowel syndrome-type symptoms in paediatric inflammatory bowel disease, and the relationship with biochemical markers of disease activity.
    Diederen K; Hoekman DR; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Vlieger AM; Kindermann A; Benninga MA
    Aliment Pharmacol Ther; 2016 Jul; 44(2):181-8. PubMed ID: 27110920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
    Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome.
    Kaiser T; Langhorst J; Wittkowski H; Becker K; Friedrich AW; Rueffer A; Dobos GJ; Roth J; Foell D
    Gut; 2007 Dec; 56(12):1706-13. PubMed ID: 17675327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with longstanding ulcerative colitis in remission do not have more irritable bowel syndrome-like symptoms than controls.
    Lundgren D; Rutegård J; Eklöf V; Palmqvist R; Karling P
    BMC Gastroenterol; 2016 Nov; 16(1):139. PubMed ID: 27881072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
    Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms.
    Kotze LM; Nisihara RM; Marion SB; Cavassani MF; Kotze PG
    Arq Gastroenterol; 2015; 52(1):50-4. PubMed ID: 26017083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Impact of Inflammatory Bowel Disease-Irritable Bowel Syndrome on Patient-reported Outcomes in CCFA Partners.
    Abdalla MI; Sandler RS; Kappelman MD; Martin CF; Chen W; Anton K; Long MD
    Inflamm Bowel Dis; 2017 Feb; 23(2):325-331. PubMed ID: 28092305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation?
    Keohane J; O'Mahony C; O'Mahony L; O'Mahony S; Quigley EM; Shanahan F
    Am J Gastroenterol; 2010 Aug; 105(8):1788, 1789-94; quiz 1795. PubMed ID: 20389294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis.
    Halpin SJ; Ford AC
    Am J Gastroenterol; 2012 Oct; 107(10):1474-82. PubMed ID: 22929759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
    Diederen K; Hoekman DR; Leek A; Wolters VM; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Benninga MA; Kindermann A
    Aliment Pharmacol Ther; 2017 Apr; 45(7):951-960. PubMed ID: 28138990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a prodromal period in Crohn's disease but not ulcerative colitis.
    Pimentel M; Chang M; Chow EJ; Tabibzadeh S; Kirit-Kiriak V; Targan SR; Lin HC
    Am J Gastroenterol; 2000 Dec; 95(12):3458-62. PubMed ID: 11151877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faecal calprotectin: a new marker for Crohn's disease?
    Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
    Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What is the faecal calprotectin test?
    Drug Ther Bull; 2014 Sep; 52(9):102-4. PubMed ID: 25213590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission.
    Jonefjäll B; Strid H; Ohman L; Svedlund J; Bergstedt A; Simren M
    Neurogastroenterol Motil; 2013 Sep; 25(9):756-e578. PubMed ID: 23731196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two immunoassays for measurement of faecal calprotectin in detection of inflammatory bowel disease: (pre)-analytical and diagnostic performance characteristics.
    Oyaert M; Trouvé C; Baert F; De Smet D; Langlois M; Vanpoucke H
    Clin Chem Lab Med; 2014 Mar; 52(3):391-7. PubMed ID: 24114912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.
    van Rheenen PF
    Inflamm Bowel Dis; 2012 Nov; 18(11):2018-25. PubMed ID: 22275341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
    Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
    Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.